Tuberculosis – burning issues: Multidrug resistance and HIV-coinfection

References

• Akolo C, Adetifa I, Shepperd S, Volmink J. (2010). Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 1, CD000171.
   Google Scholar
• Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, Haile M, Hoffner S, Joloba M, O’Brien R. (2010). Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis, 10, 41.
   PubMed Web of Science ®Google Scholar
• Bass JB Jr, Farer LS, Hopewell PC, O’Brien R, Jacobs RF, Ruben F, Snider DE Jr, Thornton G. (1994). Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med, 149, 1359–1374.
   PubMed Web of Science ®Google Scholar
• Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, Liversage T, Masibi M, van Helden PD, Warren RM, Victor TC. (2010). Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerging Infect Dis, 16, 264–271.
   PubMed Web of Science ®Google Scholar
• CDC. (1996). Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR, 45, 921–925.
   Google Scholar
• CDC. (1997). Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep, 46, 1.
   Google Scholar
• CDC. (2000a). Targeted tuberculin testing and treatment of latent tuberculosis infection. This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am J Respir Crit Care Med, 161, S221.
   Google Scholar
• CDC. (2000b). Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep, 49, 185.
   Google Scholar
• Chaisson RE, Martinson NA. (2008). Tuberculosis in Africa-combating an HIV-driven crisis. N Engl J Med, 358, 1089.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Centis R, Migliori GB. (2010). Drug-resistant tuberculosis: past, present, future. Respirology, 15, 413–432.
   PubMedGoogle Scholar
• Chikamatsu K, Mizuno K, Yamada H, Mitarai S. (2009). Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains. Kekkaku, 84, 631–633.
   PubMedGoogle Scholar
• Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. (2006). Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis, 43, 634–639.
   PubMed Web of Science ®Google Scholar
• Dartois V, Barry CE. (2006). Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (mdr) and extensively-drug resistant (xdr) tuberculosis. Kekkaku, 81(11), 693–707.
   Google Scholar
• DeodharL, MiskeenP, ChomalS. (1999). Drug resistance in tuberculosis. BHJ, 41, 253.
   Google Scholar
• Dey AB, Nagarkar K. (1995). Multi drug resistant tuberculosis. Trop Gastroenterol, 16, 92–100.
   Google Scholar
• Doucet-Populaire F, Buriánková K, Weiser J, Pernodet JL. (2002). Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord, 2, 355–370.
   PubMedGoogle Scholar
• Drobniewski F, Balabanova Y, Coker R. (2002). Clinical features, diagnosis, and management of multiple drug-resistant tuberculosis since 2002. Curr Opin Pulm Med, 10, 211–217.
   Google Scholar
• Ehsan O, Qadir MI, Malik SA, Abbasi WS, Ahmad B. (2012). Efficacy of nanogold-insulin as a hypoglycemic agent. J Chem Soc Pak.
   Google Scholar
• Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H; Swiss HIV Cohort Study. (2007). Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis, 44, 94–102.
   PubMed Web of Science ®Google Scholar
• Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. (1993). The emergence of drug-resistant tuberculosis in New York City. N Engl J Med, 328, 521–526.
   PubMed Web of Science ®Google Scholar
• Goldfeld A, Ellner JJ. (2007). Pathogenesis and management of HIV/TB co-infection in Asia. Tuberculosis (Edinb), 87 Suppl 1, S26–S30.
   Google Scholar
• Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. (2007). The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS, 21, 1441–1448.
   PubMed Web of Science ®Google Scholar
• Greenwood D. (1998). Resistance to antimicrobial agents: a personal view. J Med Microbiol, 47, 751–755.
   PubMed Web of Science ®Google Scholar
• Grobusch MP. (2010). Drug-resistant and extensively drug-resistant tuberculosis in southern Africa. Curr Opin Pulm Med, 16, 180–185.
   Google Scholar
• Horsburgh CR Jr (2004). Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med, 350, 2060–2067.
   PubMed Web of Science ®Google Scholar
• Hu Y, Hoffner S, Jiang W, Wang W, Xu B. (2010). Extensive transmission of isoniazid resistant M. tuberculosis and its association with increased multidrug-resistant TB in two rural counties of eastern China: a molecular epidemiological study. BMC Infect Dis, 10, 43.
   PubMedGoogle Scholar
• Hussain A, KhalidSH, QadirMI, MassudA, AliM, KhanIU, SaleemM, IqbalMS, AsgharS, GulH. (2011). Water uptake and drug release behaviour of methyl methacrylate-co-itaconic acid [P(MMA/IA)] hydrogels cross-linked with methylene bis-acrylamide. J Drug Delvr Sci Tech, 21(3), 249–255.
   Google Scholar
• Iseman MD. (1993). Treatment of multidrug-resistant tuberculosis. N Engl J Med, 329, 784–791.
   PubMed Web of Science ®Google Scholar
• Jain A, Dixit P. (2008). Multidrug-resistant to extensively drug resistant tuberculosis: what is next? J Biosci, 33, 605–616.
   PubMedGoogle Scholar
• Javed F, Qadir MI, Janbaz KH, Ali M. (2011). Novel drugs from marine microorganisms. Crit Rev Microbiol, 37, 245–249.
   PubMed Web of Science ®Google Scholar
• Jayaswal S, Kamal MA, Dua R, Gupta S, Majumdar T, Das G, Kumar D, Rao KV. (2010). Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog, 6, e1000839.
   Google Scholar
• Jones KD, Hesketh T, Yudkin J. (2008). Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. Trans R Soc Trop Med Hyg, 102, 219–224.
   PubMed Web of Science ®Google Scholar
• KaramatKA, HayatS, ButtT, AbbasiS. (2000). Multi-drug resistant tuberculosis. Pak Armed Forces Med J, 50(2), 114–116.
   Google Scholar
• Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS. (2010). Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 182, 113–119.
   PubMed Web of Science ®Google Scholar
• KödmönC, HolloV, HuitricE, Amato-GauciA, ManisseroD. (2010). Multidrug and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area. Euro Surveill, 15(11), pii 19519.
   Google Scholar
• Konings WN, Poelarends GJ. (2002). Bacterial multidrug resistance mediated by a homologue of the human multidrug transporter P-glycoprotein. IUBMB Life, 53, 213–218.
   PubMed Web of Science ®Google Scholar
• Lai CC, Tan CK, Lin SH, Liao CH, Huang YT, Chou CH, Hsu HL, Wang CY, Lin HI, Hsueh PR. (2010). Clinical and genotypic characteristics of extensively drug-resistant and multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 29, 597–600.
   Google Scholar
• Laing RO, McGoldrick KM. (2000). Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs. Int J Tuberc Lung Dis, 4, S194–S207.
   Google Scholar
• Loddenkemper R, Hauer B. (2010). Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch Arztebl Int, 107, 10–19.
   Google Scholar
• Loddenkemper R, Sagebiel D, Brendel A. (2002). Strategies against multidrug-resistant tuberculosis. Eur Respir J Suppl, 36, 66s–77s.
   Google Scholar
• LoddenkemperR, HauerB. (2010). Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch Arztebl Int, 107(1-2), 10–19.
   Google Scholar
• Loïez-Durocher C, Vachée A, Lemaitre N. (2000). Drug resistance in Mycobacterium tuberculosis: diagnostic methods. Ann Biol Clin (Paris), 58, 291–297.
   PubMedGoogle Scholar
• Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. (2007). Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med, 175, 737–742.
   PubMed Web of Science ®Google Scholar
• Masood MI, Qadir MI, Shirazi JH, Khan IU. (2011). Beneficial effects of lactic acid bacteria on human beings. Crit Rev Microbiol, 37, 91–98.
   PubMed Web of Science ®Google Scholar
• MendezJC. (2001). Multi drug resistance in tuberculosis and the use of PCR for defining molecular markers of resistance. Jacksonville Medicine. Available at: http://www.dcmsonline.org/jax-medicine/2001journals/Feb2001/TBresistance.htm
   Google Scholar
• Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, Vernon A, Lienhardt C, Burman W. (2009). Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med, 6, e1000146.
   Google Scholar
• Miotto P, Saleri N, Dembelé M, Ouedraogo M, Badoum G, Pinsi G, Migliori GB, Matteelli A, Cirillo DM. (2009). Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infect Dis, 9, 142.
   Google Scholar
• Morris S, Bai GH, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. (1995). Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis, 171, 954–960.
   PubMed Web of Science ®Google Scholar
• NazS, QadirMI, AliM, JanbazKH. (2012). Nanotecnology for imaging and drug delivery in cancer. J Chem Soc Pak, 34(1), 107–111.
   Google Scholar
• NisarL, QadirMI, MalikSA, TabassumN. (2011). Characterization of the immunodominant regions within gp41 of env gene of HIV in Pakistan. J Chem Soc Pak, 33(4), 545–548.
   Google Scholar
• O’Brien RJ. (1994). Drug-resistant tuberculosis: etiology, management and prevention. Semin Respir Infect, 9, 104–112.
   PubMedGoogle Scholar
• Pablos-Mendez A, Gowda DK, Frieden TR. (2002). Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ, 80, 489–95; discussion 495.
   Google Scholar
• Pablos-MéndezA, RaviglioneMC, LaszloA, BinkinN, RiederHL, BustreoF, CohnDL, CatherinaSB, WeezenbeekL, KimSJ, ChauletP, NunnP. (1998). Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med, 338, 1641–1649.
   PubMed Web of Science ®Google Scholar
• Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, Narayanan PR. (2010). First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis, 14, 243–246.
   Google Scholar
• Putman M, van Veen HW, Konings WN. (2000). Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev, 64, 672–693.
   PubMed Web of Science ®Google Scholar
• Qadir MI, Malik SA. (2010). HIV fusion inhibitors. Rev Med Virol, 20, 23–33.
   PubMedGoogle Scholar
• Qadir MI, Malik SA. (2011). Genetic variation in the HR region of the env gene of HIV: A perspective for resistance to HIV fusion inhibitors. AIDS Res Hum Retroviruses, 27, 57–63.
   PubMedGoogle Scholar
• QadirMI, MalikSA, NisaTU, TabassumN, AliS, NisarN. (2010). Characterization of HR region of gp41 of HIV. Int J Agric Biol, 12, 456–458.
   Google Scholar
• Rattan A, Kalia A, Ahmad N. (1998). Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerging Infect Dis, 4, 195–209.
   PubMed Web of Science ®Google Scholar
• Reichman LB. (1994). The challenge of drug-resistant tuberculosis. Cleve Clin J Med, 61, 431–437.
   Google Scholar
• Reichman LB. (1996). Multidrug resistance in the world: the present situation. Chemotherapy, 42 Suppl 3, 2–9; discussion 30.
   Google Scholar
• Rossetti ML, Valim AR, Silva MS, Rodrigues VS. (2002). Resistant tuberculosis: a molecular review. Rev Saude Publica, 36, 525–532.
   Google Scholar
• Segal-Maurer S, Urban C, Rahal JJ Jr. (1996). Current perspectives on multidrug-resistant bacteria. Epidemiology and control. Infect Dis Clin North Am, 10, 939–957.
   PubMed Web of Science ®Google Scholar
• ShahNS, WrightA, DrobniewskiF. (2005). Extreme drug resistance in tuberculosis “XDR-TB”: global survey of supranational reference laboratories for Mycobacterium tuberculosis with resistance to second-line drugs. Int J Tuberc Lung Dis, 9(Suppl 1), S77.
   Google Scholar
• Sharma SK, Mohan A. (2006). Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest, 130, 261–272.
   PubMed Web of Science ®Google Scholar
• Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK. (1993). Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med, 328, 1137–1144.
   PubMed Web of Science ®Google Scholar
• Telzak EE, Chirgwin KD, Nelson ET, Matts JP, Sepkowitz KA, Benson CA, Perlman DC, El-Sadr WM. (1999). Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis, 3, 337–343.
   PubMed Web of Science ®Google Scholar
• Tomioka H, Namba K. (2006). Development of antituberculous drugs: current status and future prospects. Kekkaku, 81, 753–774.
   PubMedGoogle Scholar
• Weltman AC, Rose DN. (1994). Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Arch Intern Med, 154, 2161–2167.
   Google Scholar
• World Health Organization. (2010). Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf (Accessed on January 18, 2011).
   Google Scholar